Glioblastoma Multiforme Multipeptide Vaccine IMA950

A cancer vaccine comprised of 11 peptides associated with glioblastoma multiforme (GBM), with potential immunomodulating and antineoplastic activities. Vaccination with glioblastoma multiforme multi-antigen vaccine IMA950 stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response as well as a T-helper (Th) immune response against tumor cells expressing these peptides, potentially resulting in decreased tumor growth of GBM. Peptides in IMA950 consist of the following: brevican (BCAN); chondroitin sulfate proteoglycan 4 (CSPG4); fatty acid binding protein 7, brain (FABP7); insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3); neuroligin 4, X-linked (NLGN4X); neuronal cell adhesion molecule (NRCAM); protein tyrosine phosphatase, receptor-type, Z polypeptide 1 ( PTPRZ1); tenascin C (TNC); Met proto-oncogene (MET); baculoviral IAP repeat-containing 5 (BIRC5); and hepatitis B virus core antigen. (NCI Thesaurus)

YOU MAY ALSO LIKE

Glioblastoma multiforme

A fast-growing type of central nervous system tumor that forms from glial (supportive) tissue of the brain and spinal cord and has…

Glioblastoma Cancer Vaccine ERC1671

A cancer vaccine composed of a combination of autologous glioblastoma (GBM) tumor cells, allogeneic GBM tumor cells, generated from three different GBM…

Glioblastoma by Gene Expression Profile

Classification of glioblastoma into molecular subtypes as defined by gene expression profiling.

Glioblastoma

A fast-growing type of central nervous system tumor that forms from glial (supportive) tissue of the brain and spinal cord and has…

Glimepiride

A long-acting, third-generation sulfonylurea with hypoglycemic activity. Compared to other generations of sulfonylurea compounds, glimepiride is very potent and has a longer…

Gliflumide

A fluoro-containing sulfadiazine derivative with hypoglycemic activity. Although not technically a sulfonylurea compound, gliflumide targets the sulfonylurea receptor and exerts a similar…